Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Prostate Cancer

Free Subscription 06.04.2026 2 Anticancer Res 1 BJU Int 1 BMC Urol 1 Eur J Radiol 2 Eur Radiol 2 Eur Urol 1 Int J Cancer 1 Int J Urol 1 J Clin Oncol 1 J Nucl Med 3 Lancet Oncol 1 Nat Rev Urol 2 Oncogene 1 PLoS One 10 Prostate 1 Radiol Imaging Cancer 1 Radiology 1 Ther Adv Urol 2 Urol Int

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Anticancer Res

1. YANISHI M, Shimada S, Mishima T, Kinoshita H, et al
   Real-world Comparative Study of Androgen Receptor Signaling Inhibitors in Japanese Patients With Non-metastatic Castration-resistant Prostate Cancer.
   Anticancer Res. 2026;46:2145-2151.
   PubMed         Abstract available
   
   
2. WATANABE R, Shigehisa R, Kawada T, Yamamoto S, et al
   Paired-sample Analysis of ERG Expression and TMPRSS2-ERG Fusion in Treatment-induced Neuroendocrine Prostate Cancer.
   Anticancer Res. 2026;46:1929-1942.
   PubMed         Abstract available
   
   

   
   BJU Int

3. SUSHENTSEV N, Warren AY, Colling R, Verrill C, et al
   Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial.
   BJU Int. 2026 Mar 27. doi: 10.1111/bju.70261.
   PubMed         Abstract available
   
   

   
   BMC Urol

4. ZHANG J, Chen J, Jin J, Chen J, et al
   Added value of systematic biopsy in patients with positive MRI-US fusion targeted biopsy for clinically significant prostate cancer: a single-center retrospective study.
   BMC Urol. 2026 Mar 27. doi: 10.1186/s12894-026-02123.
   PubMed        
   
   

   
   Eur J Radiol

5. ZENG Y, Shen S, Ma H, Yin R, et al
   Early prediction via PET/CT for skeletal-related events in osteoporotic men with metastatic prostate cancer undergoing androgen deprivation therapy.
   Eur J Radiol. 2026;199:112822.
   PubMed         Abstract available
   
   

   
   Eur Radiol

6. SMITH H, Stavrinides V, Giganti F, Moore CM, et al
   Reply to the Letter to the Editor: Variation in prostate cancer growth rates in an MRI-based active surveillance cohort.
   Eur Radiol. 2026 Apr 2. doi: 10.1007/s00330-026-12492.
   PubMed        
   
   
7. WANG Z, Yu C
   Letter to the Editor: Variation in prostate cancer growth rates in an MRI-based active surveillance cohort.
   Eur Radiol. 2026 Apr 1. doi: 10.1007/s00330-026-12488.
   PubMed        
   
   

   
   Eur Urol

8. KHAN S, Papa N, Kneebone A, Eade T, et al
   Prospective Comparison of (64)Copper [(64)Cu]SAR-bisPSMA vs (68)Gallium[(68)Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial).
   Eur Urol. 2026 Mar 27:S0302-2838(26)02035-X. doi: 10.1016/j.eururo.2026.
   PubMed         Abstract available
   
   
9. MONTIRONI R, Giannarini G, Cimadamore A, Lopez-Beltran A, et al
   Re: European Study of Prostate Cancer Screening - 23-Year Follow-up.
   Eur Urol. 2026 Mar 30:S0302-2838(26)02048-8. doi: 10.1016/j.eururo.2026.
   PubMed        
   
   

   
   Int J Cancer

10. MATOS B, Monteiro MV, Lagarto MR, Howl J, et al
    Screening anticancer peptides performance in organotypic prostate tumor-stroma 3D models.
    Int J Cancer. 2026;158:2936-2946.
    PubMed         Abstract available
    
    

    
    Int J Urol

11. SATO Y, Fujii Y, Kume H
    Cancer Genomic Medicine for Urological Malignancies in Japan.
    Int J Urol. 2026;33:e70449.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

12. ARMSTRONG AJ, Azad AA, Iguchi T, Stenzl A, et al
    Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.
    J Clin Oncol. 2026 Mar 27:JCO2402829. doi: 10.1200/JCO-24-02829.
    PubMed         Abstract available
    
    

    
    J Nucl Med

13. ELLS Z, Meyer C, Kimura K, Wilhalme H, et al
    Dosimetry Analysis of (177)Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial.
    J Nucl Med. 2026 Apr 2:jnumed.125.271467. doi: 10.2967/jnumed.125.271467.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

14. ALONGI F, Alongi P
    Expanding the ADT-free therapeutic landscape in oligometastatic hormone-sensitive prostate cancer.
    Lancet Oncol. 2026;27:400-402.
    PubMed        
    
    
15. PRIVE BM, Noordzij W, Muselaers CHJ, de Jong IJ, et al
    [(177)Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study.
    Lancet Oncol. 2026;27:461-469.
    PubMed         Abstract available
    
    
16. SANDHU S, Joshua AM, Emmett L, Bressel M, et al
    [(177)Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.
    Lancet Oncol. 2026;27:470-479.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

17. CHEN DM, Blum KA, Hu JC
    Evidence for metastasis-directed therapy in oligometastatic prostate cancer.
    Nat Rev Urol. 2026 Apr 3. doi: 10.1038/s41585-026-01139.
    PubMed        
    
    

    
    Oncogene

18. WEI X, Li X, Pan Y, Zhang Y, et al
    LDHA-driven lactate metabolism promotes MDSC activation and immunosuppressive microenvironment in prostate cancer.
    Oncogene. 2026 Apr 1. doi: 10.1038/s41388-026-03737.
    PubMed         Abstract available
    
    
19. LI N, Zoubeidi A, Beraldi E, Gleave ME, et al
    Editorial Expression of Concern: GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer.
    Oncogene. 2026 Mar 30. doi: 10.1038/s41388-026-03770.
    PubMed        
    
    

    
    PLoS One

20. YUAN X, Chen Y, Lu H, Zheng P, et al
    A survivorship-oriented enhanced care model for patients undergoing radical prostatectomy.
    PLoS One. 2026;21:e0346609.
    PubMed         Abstract available
    
    

    
    Prostate

21. OZLU DN, Arikan Y, Emir B, Ayten A, et al
    Development of Machine Learning Models for Predicting Prostate Cancer in Biopsy Candidates Using Prostate-Specific Antigen, Magnetic Resonance Imaging, and Hematologic Parameters.
    Prostate. 2026 Mar 30. doi: 10.1002/pros.70168.
    PubMed         Abstract available
    
    
22. SKOWRON AT, Childers K, Rose CM, McElyea KC, et al
    Socioeconomic and Demographic Factors in Genetic Testing Utilization Among Advanced Prostate Cancer Patients.
    Prostate. 2026 Mar 30. doi: 10.1002/pros.70165.
    PubMed         Abstract available
    
    
23. ONAL C, Elmali A, Demirhan B, Senturk E, et al
    Impact of Intraprostatic Simultaneous Integrated Boost on Long-Term Outcomes in Unfavorable Intermediate-Risk Prostate Cancer Treated With Dose-Escalated Radiotherapy and Short-Term Androgen Deprivation Therapy.
    Prostate. 2026 Mar 30. doi: 10.1002/pros.70167.
    PubMed         Abstract available
    
    
24. BAUER N, Fankhauser CD, Sigg S, Kaufmann E, et al
    Toward a Modern Telehealth Follow-Up Routine for Radical Prostatectomy: Introducing a Novel E-Health Application for Outcome and Complication Assessment.
    Prostate. 2026;86:718-726.
    PubMed         Abstract available
    
    
25. DARBANDI S, Urbanucci A, Hakkola S, Gujral J, et al
    Happening in the Prostate Tumor Microenvironment: Ion Channels and Extrachromosomal DNA Driving Phenotypic Plasticity.
    Prostate. 2026;86:619-636.
    PubMed         Abstract available
    
    
26. DOBREV H
    The Sign of Leser-Trelat as a Possible Indicator of Prostate Adenocarcinoma: A Case Report.
    Prostate. 2026;86:732-734.
    PubMed         Abstract available
    
    
27. OZAWA Y, Moschovas MC, Sandri M, Sharma R, et al
    Incremental Predictive Value of the Oncotype Genomic Prostate Score for Adverse Pathology in Active Surveillance Candidates.
    Prostate. 2026;86:637-647.
    PubMed         Abstract available
    
    
28. TAYLOR KG, Johannessen B, Mills IG, Rye MB, et al
    Spatial Robustness of Prostate Cancer Biomarkers Evaluated by Spatial Transcriptomics.
    Prostate. 2026 Mar 30. doi: 10.1002/pros.70164.
    PubMed         Abstract available
    
    
29. HAN X, Zhao X, Zhang N, Yang D, et al
    Global Trends in Prostate Cancer Incidence Among Men Aged 55+ (1992-2021): An Age-Period-Cohort Analysis.
    Prostate. 2026 Mar 30. doi: 10.1002/pros.70166.
    PubMed         Abstract available
    
    
30. KUROKAWA K, Yamamoto S, Yamada Y, Sato K, et al
    A Two-Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone-Sensitive Prostate Cancer.
    Prostate. 2026 Mar 31. doi: 10.1002/pros.70171.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

31. HOLZGREVE A, Calais J
    Virchow Node in Prostate Cancer.
    Radiol Imaging Cancer. 2026;8:e250681.
    PubMed        
    
    

    
    Radiology

32. GHODSI A, Owens L, Demirci RA, Gafita A, et al
    PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving (177)Lu-PSMA-617.
    Radiology. 2026;318:e250649.
    PubMed         Abstract available
    
    

    
    Ther Adv Urol

33. SANYAL C, Rendon R
    Cost-effectiveness of PSMA-PET imaging technology in diagnosing and staging of prostate cancer: a systematic review.
    Ther Adv Urol. 2026;18:17562872261436874.
    PubMed         Abstract available
    
    

    
    Urol Int

34. SCHOSTAK M, Peklo E, Peters I, Machtens S, et al
    Parameters predicting Recurrence after Focal Therapy for Prostate Cancer: Insights from a Multicenter Surveillance Database.
    Urol Int. 2026 Apr 2:1-20. doi: 10.1159/000551632.
    PubMed         Abstract available
    
    
35. ELLEISY M, Resch I, Yurdakul O, Hubner NA, et al
    Acute Kidney Injury in a Cancer Patient Exposed to Relugolix and Abiraterone.
    Urol Int. 2026;110:198-201.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum